JP2007505033A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505033A5
JP2007505033A5 JP2006519734A JP2006519734A JP2007505033A5 JP 2007505033 A5 JP2007505033 A5 JP 2007505033A5 JP 2006519734 A JP2006519734 A JP 2006519734A JP 2006519734 A JP2006519734 A JP 2006519734A JP 2007505033 A5 JP2007505033 A5 JP 2007505033A5
Authority
JP
Japan
Prior art keywords
seq
composition
amino acid
acid sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006519734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505033A (ja
Filing date
Publication date
Priority claimed from US10/888,805 external-priority patent/US7368537B2/en
Application filed filed Critical
Publication of JP2007505033A publication Critical patent/JP2007505033A/ja
Publication of JP2007505033A5 publication Critical patent/JP2007505033A5/ja
Pending legal-status Critical Current

Links

JP2006519734A 2003-07-15 2004-07-14 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン Pending JP2007505033A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48780403P 2003-07-15 2003-07-15
US56758604P 2004-05-03 2004-05-03
US10/888,805 US7368537B2 (en) 2003-07-15 2004-07-09 Subunit vaccine against respiratory syncytial virus infection
PCT/CA2004/001007 WO2005007189A1 (en) 2003-07-15 2004-07-14 Subunit vaccine against respiratory syncytial virus infection

Publications (2)

Publication Number Publication Date
JP2007505033A JP2007505033A (ja) 2007-03-08
JP2007505033A5 true JP2007505033A5 (https=) 2007-08-30

Family

ID=34084525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006519734A Pending JP2007505033A (ja) 2003-07-15 2004-07-14 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン

Country Status (9)

Country Link
US (2) US7368537B2 (https=)
EP (2) EP1651264B1 (https=)
JP (1) JP2007505033A (https=)
AT (1) ATE451119T1 (https=)
AU (1) AU2004257363A1 (https=)
CA (1) CA2532164A1 (https=)
DE (1) DE602004024542D1 (https=)
ES (1) ES2337901T3 (https=)
WO (1) WO2005007189A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238471D1 (de) * 2001-03-09 2011-01-13 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
ATE472336T1 (de) 2003-10-22 2010-07-15 Id Biomedical Corp Quebec Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
CA2571035A1 (en) * 2004-06-25 2006-01-12 Id Biomedical Corporation Of Quebec Compositions and methods for treating neurological disorders
PL2222710T3 (pl) 2007-12-24 2017-01-31 Id Biomedical Corporation Of Quebec Rekombinowane antygeny rsv
MX2011000668A (es) * 2008-07-18 2011-07-29 Id Biomedical Corp Quebec Antigenos quimericos polipeptidicos del virus sincitial respiratorio.
US20110318376A1 (en) * 2008-12-24 2011-12-29 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
MX2012000035A (es) 2009-06-24 2012-02-28 Id Biomedical Corp Quebec Antigenos de virus de sincicio respiratorio recombinantes.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
US8846056B2 (en) * 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
US8730396B2 (en) * 2010-06-23 2014-05-20 MindTree Limited Capturing events of interest by spatio-temporal video analysis
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
RS63817B1 (sr) * 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
CN103037898B (zh) 2010-07-07 2016-06-29 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
RS63890B1 (sr) * 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
PT3970742T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2862871C (en) * 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
RU2456020C1 (ru) * 2011-03-30 2012-07-20 Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) Способ профилактики гриппа и острых респираторных инфекций у детей с бронхиальной астмой
CA2834349A1 (en) * 2011-04-26 2012-11-01 Molecular Express, Inc. Liposomal formulations
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
MY171498A (en) 2012-08-01 2019-10-15 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
US9415101B2 (en) * 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
KR101695518B1 (ko) * 2014-09-30 2017-01-12 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 범용 백신
JP7086000B2 (ja) 2015-11-10 2022-06-17 オハイオ・ステート・イノヴェーション・ファウンデーション 体液性親和性の加速に関する方法及び組成物
CA3079604A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
EP3833677A4 (en) 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
IL123720A (en) 1995-09-18 2002-02-10 Us Army Medical Res Material C Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
US5848152A (en) 1995-09-26 1998-12-08 Motorola, Inc. Communication device having interchangeable faceplates and active keypad cover
US6699478B1 (en) 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
PT1015595E (pt) 1997-09-19 2005-05-31 Wyeth Corp Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio
WO2001060402A2 (en) 2000-02-15 2001-08-23 Intellivax International Inc. Proteosome influenza vaccine
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
DE60238471D1 (de) * 2001-03-09 2011-01-13 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection

Similar Documents

Publication Publication Date Title
JP2007505033A5 (https=)
Aguilar et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen
Manocha et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target
US4474757A (en) Synthetic vaccine and process for producing same
Tamura et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine
JP2012501959A5 (https=)
JP7403733B2 (ja) インフルエンザｈａスプリットワクチンの製造方法
WO1999014334A1 (en) Peptides derived from the attachment (g) protein of respiratory syncytial virus
Kimoto et al. Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF‐10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses
KR100341958B1 (ko) 백신조성물
WO2019045090A1 (ja) インフルエンザｈａスプリットワクチンの製造方法
AU2022262841A9 (en) Compositions and methods for preventing rsv and piv3 infections
US7527798B2 (en) Composition and method for preventing or treating a virus infection
US7354589B2 (en) Multiple antigenic agents and methods for using the same
Park et al. Effect of epitope-CpG-DNA-liposome complex without carriers on vaccination of respiratory syncytial virus infection
JP2020050605A (ja) 粘膜アジュバント
WO2012053856A3 (ko) 호흡기 신시치아 바이러스 백신 조성물 및 그의 제조방법
US7740860B2 (en) Composition and method for preventing or treating a virus infection
Nguyen et al. Subunit vaccine candidates engineered from the central conserved region of the RSV G protein aimed for parenteral or mucosal delivery
de Haan et al. Evaluation of a liposome-supplemented intranasal influenza subunit vaccine in a murine model system: induction of systemic and local mucosal immunity
CA2168885C (en) Vaccine compositions
李秀玲 et al. Development of RSV Vaccines
MX2008005634A (en) Prime boost vaccine for the protection of equines against equine influenza